Robert W. Duggan - 29 Nov 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Director, 10%+ Owner
Signature: /s/ Ken Stratton
Issuer symbol: PLSE
Transactions as of: 29 Nov 2023
Net transactions value: +$2,059,703
Form type: 4
Filing time: 01 Dec 2023, 19:36:48 UTC
Previous filing: 30 Nov 2023
Next filing: 04 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Options Exercise	$9,919	+1,667	+0%	$5.95	36,392,861	29 Nov 2023	Direct
transaction	PLSE	Common Stock	Purchase	$1,497,184	+158,600	+0.44%	$9.44	36,551,461	29 Nov 2023	Direct	F1
transaction	PLSE	Common Stock	Purchase	$552,600	+60,000		$9.21	60,000	29 Nov 2023	See footnote	F1, F2
holding	PLSE	Common Stock						492,069	29 Nov 2023	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Options Exercise	$0	-1,667	-14%	$0.000000	10,000	29 Nov 2023	Common Stock	1,667	$5.95	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Volume-weighted average price.
F2	Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
F3	Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
F4	Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting.